RXRX Stock Analysis: Buy, Sell, or Hold?
RXRX - Recursion Pharmaceuticals, Inc. Class A Common Stock
$3.80
0.13 (3.54%)
▲
5d:
+13.77%
30d:
+5.26%
90d:
+24.18%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Smart Money Accumulation
None View Scanner →
Strength: 8.6/10
Get Alerted When RXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RXRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RXRX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RXRX is currently trading at $3.80, which is considered extended relative to its 30-day fair value range of $3.13 to $3.62.
Technical Outlook: Technically, RXRX is in a uptrend. Immediate support is located at $3.09, while resistance sits at $4.04. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: RXRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.64 (+74.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RXRX is in a uptrend. Immediate support is located at $3.09, while resistance sits at $4.04. The stock is showing strong short-term momentum, up 3.5% recently.
Market Sentiment: RXRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.64 (+74.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.13 -
$3.62
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.5%)
- BULLISH: Trading 74.8% below Wall St target ($6.64)
Trading Range Analysis
30-Day Trading Range
$3.13 -
$3.62
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.09
Resistance Level
$4.04
Current Trend
Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.32
Wall Street Target
$6.64
(+74.8%)
Revenue Growth (YoY)
-56.1%
Share & Embed Analysis
Last updated: July 02, 2026 10:46 PM ET
Data refreshes hourly during market hours. Next update: 11:46 PM
Data refreshes hourly during market hours. Next update: 11:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RXRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Blake Borgeson
SELL
30000 shares
2026-04-07
Ben R Taylor
SELL
7956 shares
2026-03-17
Najat Khan
SELL
28298 shares
2026-03-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
Advanced RXRX Option Strategies
Professional options setups generated by AI based on today's RXRX price and gamma walls.
